Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

  • 1,935 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • …
  • 138
  • 139
  • 140
  • …
  • 193
  • 194
  • Next →
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
Sergio Dias, … , M.A.S. Moore, Shahin Rafii
Sergio Dias, … , M.A.S. Moore, Shahin Rafii
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):511-521. https://doi.org/10.1172/JCI8978.
View: Text | PDF

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

  • Text
  • PDF
Abstract

Emerging data suggest that VEGF receptors are expressed by endothelial cells as well as hematopoietic stem cells. Therefore, we hypothesized that functional VEGF receptors may also be expressed in malignant counterparts of hematopoietic stem cells such as leukemias. We demonstrate that certain leukemias not only produce VEGF but also express functional VEGFR-2 in vivo and in vitro, resulting in the generation of an autocrine loop that may support leukemic cell survival and proliferation. Approximately 50% of freshly isolated leukemias expressed mRNA and protein for VEGFR-2. VEGF165 induced phosphorylation of VEGFR-2 and increased proliferation of leukemic cells, demonstrating these receptors were functional. VEGF165 also induced the expression of MMP-9 by leukemic cells and promoted their migration through reconstituted basement membrane. The neutralizing mAb IMC-1C11, specific to human VEGFR-2, inhibited leukemic cell survival in vitro and blocked VEGF165-mediated proliferation of leukemic cells and VEGF-induced leukemic cell migration. Xenotransplantation of primary leukemias and leukemic cell lines into immunocompromised nonobese diabetic mice resulted in significant elevation of human, but not murine, VEGF in plasma and death of inoculated mice within 3 weeks. Injection of IMC-1C11 inhibited proliferation of xenotransplanted human leukemias and significantly increased the survival of inoculated mice. Interruption of signaling by VEGFRs, particularly VEGFR-2, may provide a novel strategy for inhibiting leukemic cell proliferation.

Authors

Sergio Dias, Koichi Hattori, Zhenping Zhu, Beate Heissig, Margaret Choy, William Lane, Yan Wu, Amy Chadburn, Elizabeth Hyjek, Muhammad Gill, Daniel J. Hicklin, Larry Witte, M.A.S. Moore, Shahin Rafii

×

Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice
Andrew C. Li, … , Wulf Palinski, Christopher K. Glass
Andrew C. Li, … , Wulf Palinski, Christopher K. Glass
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):523-531. https://doi.org/10.1172/JCI10370.
View: Text | PDF

Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice

  • Text
  • PDF
Abstract

The peroxisome proliferator–activated receptor γ (PPARγ) is a nuclear receptor that regulates fat-cell development and glucose homeostasis and is the molecular target of a class of insulin-sensitizing agents used for the management of type 2 diabetes mellitus. PPARγ is highly expressed in macrophage foam cells of atherosclerotic lesions and has been demonstrated in cultured macrophages to both positively and negatively regulate genes implicated in the development of atherosclerosis. We report here that the PPARγ-specific agonists rosiglitazone and GW7845 strongly inhibited the development of atherosclerosis in LDL receptor–deficient male mice, despite increased expression of the CD36 scavenger receptor in the arterial wall. The antiatherogenic effect in male mice was correlated with improved insulin sensitivity and decreased tissue expression of TNF-α and gelatinase B, indicating both systemic and local actions of PPARγ. These findings suggest that PPARγ agonists may exert antiatherogenic effects in diabetic patients and provide impetus for efforts to develop PPARγ ligands that separate proatherogenic activities from antidiabetic and antiatherogenic activities.

Authors

Andrew C. Li, Kathleen K. Brown, Mercedes J. Silvestre, Timothy M. Willson, Wulf Palinski, Christopher K. Glass

×

Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis
Theodore J. Koh, … , Andrea Varro, Timothy C. Wang
Theodore J. Koh, … , Andrea Varro, Timothy C. Wang
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):533-539. https://doi.org/10.1172/JCI9476.
View: Text | PDF

Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis

  • Text
  • PDF
Abstract

Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene occur in most colorectal cancers and lead to activation of β-catenin. Whereas several downstream targets of β-catenin have been identified (c-myc, cyclin D1, PPARδ), the precise functional significance of many of these targets has not been examined directly using genetic approaches. Previous studies have shown that the gene encoding the hormone gastrin is activated during colon cancer progression and the less-processed forms of gastrin are important colonic trophic factors. We show here that the gastrin gene is a downstream target of the β-catenin/TCF-4 signaling pathway and that cotransfection of a constitutively active β-catenin expression construct causes a threefold increase in gastrin promoter activity. APCmin–/+ mice overexpressing one of the alternatively processed forms of gastrin, glycine-extended gastrin, show a significant increase in polyp number. Gastrin-deficient APCmin–/+ mice, conversely, showed a marked decrease in polyp number and a significantly decreased polyp proliferation rate. Activation of gastrin by β-catenin may therefore represent an early event in colorectal tumorigenesis and may contribute significantly toward neoplastic progression. The identification of gastrin as a functionally relevant downstream target of the β-catenin signaling pathway provides a new target for therapeutic modalities in the treatment of colorectal cancer.

Authors

Theodore J. Koh, Clemens J. Bulitta, John V. Fleming, Graham J. Dockray, Andrea Varro, Timothy C. Wang

×

Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor
Yasuaki Hata, … , Sven E. Bursell, Lloyd Paul Aiello
Yasuaki Hata, … , Sven E. Bursell, Lloyd Paul Aiello
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):541-550. https://doi.org/10.1172/JCI8338.
View: Text | PDF

Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor

  • Text
  • PDF
Abstract

Prostacyclin-stimulating factor (PSF) acts on vascular endothelial cells to stimulate the synthesis of the vasodilatory molecule prostacyclin (PGI2). We have examined the expression, regulation, and hemodynamic bioactivity of PSF both in whole retina and in cultured cells derived from this tissue. PSF was expressed in all retinal cell types examined in vitro, but immunohistochemical analysis revealed PSF mainly associated with retinal vessels. PSF expression was constitutive in retinal pericytes (RPCs) but could be modulated in bovine retinal capillary endothelial cells (RECs) by cell confluency, hypoxia, serum starvation, high glucose concentrations, or inversely by soluble factors present in early vs. late retinopathy, such as TGF-β, VEGF, or bFGF. In addition, RPC-conditioned media dramatically increased REC PGI2 production, a response inhibited by blocking PSF with a specific antisense oligodeoxynucleotide (ODN). In vivo, PGI2 increased retinal blood flow (RBF) in control and diabetic animals. Furthermore, the early drop in RBF during the initial weeks after inducing diabetes in rats, as well as the later increase in RBF, both correlated with levels of retinal PSF. RBF also responded to treatment with RPC-conditioned media, and this effect could be partially blocked using the antisense PSF ODN. We conclude that PSF expressed by ocular cells can induce PGI2, retinal vascular dilation, and increased retinal blood flow, and that alterations in retinal PSF expression may explain the biphasic changes in RBF observed in diabetes.

Authors

Yasuaki Hata, Allen Clermont, Teruaki Yamauchi, Eric A. Pierce, Izumi Suzuma, Hiroyuki Kagokawa, Hiroshi Yoshikawa, Gregory S. Robinson, Tatsuro Ishibashi, Toshihiko Hashimoto, Fumio Umeda, Sven E. Bursell, Lloyd Paul Aiello

×

Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation
Bart N. Lambrecht, … , Kris Thielemans, Romain A. Pauwels
Bart N. Lambrecht, … , Kris Thielemans, Romain A. Pauwels
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):551-559. https://doi.org/10.1172/JCI8107.
View: Text | PDF

Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation

  • Text
  • PDF
Abstract

The aim of this study was to investigate whether dendritic cells (DCs) can induce sensitization to aeroallergen in a mouse model of allergic asthma. Ovalbumin-pulsed (OVA-pulsed) or unpulsed myeloid DCs that were injected into the airways of naive mice migrated into the mediastinal lymph nodes. When challenged 2 weeks later with an aerosol of OVA, activated CD4 and CD8 lymphocytes, eosinophils, and neutrophils were recruited to the lungs of actively immunized mice. These CD4+ lymphocytes produced predominantly IL-4 and IL-5 but also IFN-γ, whereas CD8+ lymphocytes produced predominantly IFN-γ. Histological analysis revealed perivascular and peribronchial eosinophilic infiltrates and goblet cell hyperplasia. Studies in IL-4–/– and CD28–/– mice revealed that production of IL-4 by host cells and provision of costimulation to T cells by DCs were critical for inducing the response. Lung CD4+ T cells strongly expressed the Th2 marker T1/ST2, and signaling through this molecule via a ligand expressed on DCs was essential for the establishment of airway eosinophilia. These data demonstrate that DCs in the airways induce sensitization to inhaled antigen and that molecules expressed on the surface of these cells are critical for the development of Th2-dependent airway eosinophilia.

Authors

Bart N. Lambrecht, Marijke De Veerman, Anthony J. Coyle, Jose-Carlos Gutierrez-Ramos, Kris Thielemans, Romain A. Pauwels

×

Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A
Utpal Pal, … , Yves Lobet, Erol Fikrig
Utpal Pal, … , Yves Lobet, Erol Fikrig
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):561-569. https://doi.org/10.1172/JCI9427.
View: Text | PDF

Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A

  • Text
  • PDF
Abstract

Borrelia burgdorferi outer surface protein (Osp) A has been used as a Lyme disease vaccine that blocks transmission: OspA antibodies of immune hosts enter ticks during blood feeding and destroy spirochetes before transmission to the host can occur. B. burgdorferi produce OspA in the gut of unfed Ixodes scapularis ticks, and many spirochetes repress OspA production during the feeding process. This preferential expression suggests that OspA may have an important function in the vector. Here we show that OspA mediates spirochete attachment to the tick gut by binding to an I. scapularis protein. The binding domains reside in the central region and COOH-terminus of OspA. OspA also binds to itself, suggesting that spirochete-spirochete interactions may further facilitate adherence in the gut. OspA-mediated attachment in the tick provides a possible mechanism for how stage-specific protein expression can contribute to pathogenesis during the B. burgdorferi natural cycle.

Authors

Utpal Pal, Aravinda M. de Silva, Ruth R. Montgomery, Durland Fish, Juan Anguita, John F. Anderson, Yves Lobet, Erol Fikrig

×

Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice
Gina C. Schatteman, … , Sherry G. Dodds, Barbara A. Christy
Gina C. Schatteman, … , Sherry G. Dodds, Barbara A. Christy
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):571-578. https://doi.org/10.1172/JCI9087.
View: Text | PDF

Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice

  • Text
  • PDF
Abstract

Endothelial cell progenitors, angioblasts, have been detected in the peripheral blood of adult humans, mice, and rabbits. These cells have been shown to incorporate into the endothelium of newly forming blood vessels in pathological and nonpathological conditions. Here we investigated the possibility that the CD34-expressing leukocytes (CD34+ cells) that appear to be enriched for angioblasts could be used to accelerate the rate of blood-flow restoration in nondiabetic and diabetic mice undergoing neovascularization due to hindlimb ischemia. CD34+ cells did not accelerate the restoration of flow in nondiabetic mice, but dramatically increased it in diabetic mice. Furthermore, CD34+ cells derived from type 1 diabetics produced fewer differentiated endothelial cells in culture than did their type 2 diabetic– or nondiabetic-derived counterparts. In vitro experiments suggest that hyperglycemia per se does not alter the ability of angioblasts to differentiate or of angioblast-derived endothelial cells to proliferate. In contrast, hyperinsulinemia may enhance angioblast differentiation but impair angioblast-derived endothelial cell survival or proliferation. Our findings suggest that CD34+ cells may be a useful tool for therapeutic angiogenesis in diabetics.

Authors

Gina C. Schatteman, Heather D. Hanlon, Chunhua Jiao, Sherry G. Dodds, Barbara A. Christy

×

Thrombin activates a Y box–binding protein (DNA-binding protein B) in endothelial cells
Olga I. Stenina, … , Earl J. Poptic, Paul E. DiCorleto
Olga I. Stenina, … , Earl J. Poptic, Paul E. DiCorleto
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):579-587. https://doi.org/10.1172/JCI9075.
View: Text | PDF

Thrombin activates a Y box–binding protein (DNA-binding protein B) in endothelial cells

  • Text
  • PDF
Abstract

Thrombin stimulates the expression of multiple genes in endothelial cells (ECs), but the trans-acting factors responsible for this induction remain undefined. We have previously described a thrombin-inducible nuclear factor (TINF), which binds to an element in the PDGF B promoter and is responsible for the thrombin inducibility of this gene. Inactive cytoplasmic TINF is rapidly activated and translocated to nuclei of ECs upon stimulation with thrombin. We have now purified TINF from thrombin-treated ECs. Amino acid sequencing revealed it to be a member of the Y-box protein family, and the sole Y-box protein–encoding cDNA we detected in human or bovine ECs corresponded to DNA-binding protein B (dbpB). DbpB translocated to the nucleus after thrombin stimulation of ECs as shown by FACS analysis of nuclei from ECs expressing GFP-dbpB fusion proteins. During thrombin activation, dbpB was found to be cleaved, yielding a 30-kDa NH2-terminal fragment that recognized the thrombin-response element sequence, but not the Y-box consensus sequence. Preincubation of ECs with protein tyrosine phosphatase inhibitors completely blocked dbpB activation by thrombin and blocked induction of endogenous PDGF B–chain mRNA and promoter activation by thrombin. Y-box proteins are known to act constitutively to regulate the expression of several genes. Activation of this class of transcription factors in response to thrombin or any other agonist represents a novel signaling pathway.

Authors

Olga I. Stenina, Earl J. Poptic, Paul E. DiCorleto

×

Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression
Toshiaki Kadokami, … , Carole S. Frye, Arthur M. Feldman
Toshiaki Kadokami, … , Carole S. Frye, Arthur M. Feldman
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):589-597. https://doi.org/10.1172/JCI9307.
View: Text | PDF

Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression

  • Text
  • PDF
Abstract

Epidemiological evidence suggests that the prognosis of heart failure in women is better than in men. In our murine model of dilated cardiomyopathy arising from cardiac-specific overexpression of TNF-α, the 6-month survival rate was significantly better in females than in males. Young female transgenic mice exhibited left ventricular wall thickening without dilatation, whereas age-matched male transgenic hearts were markedly dilated. Basal and isoproterenol-stimulated fractional shortening was preserved in female transgenic mice, but not in male transgenic mice. Myocardial expression of proinflammatory cytokines and the extent of myocardial infiltrates were similar in male and female transgenic mice. Myocardial expression of TNF-receptor mRNAs (type I and type II) was significantly higher in male mice in both transgenic and wild-type littermates, whereas sex-specific differences were not observed in either peripheral white blood cells or liver tissue. After TNF-α challenge, myocardial but not liver production of ceramide was significantly higher in male than in female mice. Thus, differential expression of myocardial TNF receptors may contribute to sex differences in the severity of congestive heart failure and mortality consequent to cardiac-specific overexpression of TNF-α.

Authors

Toshiaki Kadokami, Charles F. McTiernan, Toru Kubota, Carole S. Frye, Arthur M. Feldman

×

Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene
Jing Jin Gu, … , Lanier Ayscue, Beverly S. Mitchell
Jing Jin Gu, … , Lanier Ayscue, Beverly S. Mitchell
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):599-606. https://doi.org/10.1172/JCI8669.
View: Text | PDF

Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene

  • Text
  • PDF
Abstract

Inosine 5′-monophosphate dehydrogenase (IMPDH) is the rate-limiting enzyme in the de novo synthesis of guanine nucleotides, which are also synthesized from guanine by a salvage reaction catalyzed by the X chromosome–linked enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT). Since inhibitors of IMPDH are in clinical use as immunosuppressive agents, we have examined the consequences of knocking out the IMPDH type II enzyme by gene targeting in a mouse model. Loss of both alleles of the gene encoding this enzyme results in very early embryonic lethality despite the presence of IMPDH type I and HPRT activities. Lymphocytes from IMPDH II+/– heterozygous mice are normal with respect to subpopulation distribution and respond normally to a variety of mitogenic stimuli. However, mice with an IMPDH II+/–, HPRT–/o genotype demonstrate significantly decreased lymphocyte responsiveness to stimulation with anti-CD3 and anti-CD28 antibodies and show a 30% mean reduction in GTP levels in lymphocytes activated by these antibodies. Furthermore, the cytolytic activity of their T cells against allogeneic target cells is significantly impaired. These results demonstrate that a moderate decrease in the ability of murine lymphocytes to synthesize guanine nucleotides during stimulation results in significant impairment in T-cell activation and function.

Authors

Jing Jin Gu, Sander Stegmann, Karen Gathy, Robert Murray, Josee Laliberte, Lanier Ayscue, Beverly S. Mitchell

×
  • ← Previous
  • 1
  • 2
  • …
  • 138
  • 139
  • 140
  • …
  • 193
  • 194
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts